Rivus Pharmaceuticals is a Charlottesville, VA–based clinical-stage biopharmaceutical company focused on mitochondrial biology and advancing a new class of medicines called Controlled Metabolic Accelerators (CMAs). Its lead small-molecule candidate, HU6, is designed to safely harness mitochondrial uncoupling to selectively reduce fat and address obesity, a primary driver of cardio-metabolic disease. Earlier this year the company released Phase 2a metabolic study data in obese participants that provided proof-of-concept validation for CMAs. Rivus positions HU6 as a potential treatment across a range of cardio-metabolic indications, including obesity, HFpEF, type 2 diabetes and NAFLD/NASH. The company intends to use recent financing to advance HU6 through clinical development. Allen Cunningham serves as President and CEO. Rivus Pharmaceuticals is a Charlottesville, Va.-based biopharmaceutical company focused on improving cardio-metabolic health. It is developing a new class of oral, once-daily small-molecule therapeutics called Controlled Metabolic Accelerators (CMAs) to treat underlying causes of metabolic and cardiovascular diseases. CMAs are designed to activate mitochondrial uncoupling in a measured way by ferrying protons out of the mitochondrial intermembrane space, which cues increased oxidation of sugars and fats while maintaining baseline ATP production. This mechanism is intended to reduce accumulated fat and prevent additional fat accumulation across the body. The company is advancing a pipeline targeting type 2 diabetes, severe hypertriglyceridemia, non-alcoholic steatohepatitis and heart failure with preserved ejection fraction (HFpEF). Rivus is led by President and CEO Allen Cunningham and is currently conducting a Phase 2a clinical study with its lead CMA therapeutic, HU6. It closed a $35m Series A to fund continued development of its pipeline.

Total raised

$167M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2022